NovoCure Ltd 8-K

What Happened

• On March 26, 2026 NovoCure filed an 8-K (Item 7.01, Regulation FD Disclosure) and issued a press release announcing positive topline results from the Phase 2 PANOVA-4 trial.
• The trial tested Tumor Treating Fields (TTFields) given together with atezolizumab (Tecentriq®), gemcitabine and nab‑paclitaxel as first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). PANOVA-4 met its pre-specified primary endpoint, showing a statistically significant improvement in disease control rate (DCR) versus a historical control.

Key Details

• DCR with TTFields + atezolizumab + gemcitabine/nab‑paclitaxel: 74.4% (N = 78).
• Historical control (MPACT Phase 3 study, gem/nab‑paclitaxel alone): DCR = 48% (N = 431).
• Difference = 26.4%; one-sided p-value < 0.001, meeting the trial’s primary endpoint.
• Disclosure filed March 26, 2026; the announcement was provided via press release (Exhibit 99.1).

Why It Matters

• This is an early (Phase 2) positive efficacy signal for NovoCure’s TTFields therapy in a difficult-to-treat cancer (mPDAC). A materially higher disease control rate versus the historical MPACT control suggests potential added benefit when TTFields are combined with immunotherapy and standard chemotherapy.
• For investors, the result could support continued clinical development and future regulatory and commercial discussions, but it is not a final efficacy or survival outcome (Phase 3 confirmation and additional endpoints would be needed).
• The filing is a Regulation FD disclosure of the press release; it does not itself change financial statements or report clinical approvals.